2026年2月4日，GE 医疗发布 2025 年第四季度及全年业绩。 在全球医疗设备行业整体仍受宏观波动、贸易环境变化与成本压力影响的背景下，GE 医疗交出了一份 收 入与每股收益均超出市场预期 的年报，并同步给出了指向明确的 2026 年增长与利润修复指引。 这份年报的价值在于其所呈现出的 增长结构、盈利弹性以及对外部冲击的吸收能力 。 # 全年表现：收入温和增长，但"质量"并不保守 从全年结果看，GE 医疗 2025 年实现营收 206亿美元 （约合人民币1430亿） ，同比增长 4.8% ，其中 有机收入增长 3.5% 。 在大型医疗设备公司中，这一增速并不激进，但其来源具有相当明确的结构性支撑。 驱动增长的核心业务包括： 三大板块共同贡献了全年收入的主要增量，而非依赖单一明星产品或短期项目集中释放。 更重要的是订单端的表现： 在医疗设备行业，这一组合意味着两点： 一是收入增长并非"透支式兑现"；二是公司在手订单（backlog） 为 2026 年提供了较好的可见度。 但利润端则出现阶段性回落： Imaging（影像） Pharmaceutical Diagnostics（药物诊断，PDx） Advan ...

LOS ANGELES, Feb. 03, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services and a global developer of digital health solutions, announced today that it has acquired the outpatient imaging assets of Northwest Radiology Network, P.C., marking the company’s entry into Indiana and expanding RadNet’s presence into the Midwestern United States. The six acquired multimodality outpatient centers are located in the gre ...

产业策略 [table_Header]2026.02.03 医药产业运行数据专题：减速提质，创新渐入 佳境 产业研究中心 摘要： | [Table_Authors] | | | --- | --- | | | 丁丹(分析师) | | | 0755-23976735 | | | dingdan@gtht.com | | 登记编号 | S0880514030001 | | | 贺文斌(分析师) | | | 010-68067998 | | | hewenbin@gtht.com | | 登记编号 | S0880525040034 | | | 张拓(分析师) | | | 0755-23976170 | | | zhangtuo@gtht.com | | 登记编号 | S0880523090003 | [Table_Report] 往期回顾 走向积极所有权：治理觉醒与价值重塑——2026 年全球可持续投资趋势展望 2026.01.12 国企竞争力提升与上海国资实践 2025.12.22 呼吸系统专题（一）：慢阻肺治疗缺口突出， PDE3/4 及多疗法共破局 2025.09.26 医药上市公司 2025 中报专题：创新 ...

Core Viewpoint - WanDong Medical is expected to report a significant net loss for 2025, transitioning from a profitable state to a phase of pressure on earnings [1][3]. Performance Overview - The company forecasts a net profit attributable to shareholders of between -199 million to -257 million yuan for 2025. - The net profit after deducting non-recurring items is expected to be between -213 million to -271 million yuan. - In contrast, the company achieved a net profit of 157 million yuan in 2024, with a net profit of 142 million yuan after deducting non-recurring items, indicating a clear reversal in performance for 2025 [3]. Reasons for Performance Pressure - The decline in performance for 2025 is attributed to three main factors: 1. The impact of centralized procurement and price adjustments on gross profit margins. The company is participating in centralized procurement for medical equipment, adopting more competitive pricing strategies to increase bid success rates, which compresses product gross margins and affects current profits [4]. 2. Increased R&D investment leading to short-term cost pressures. The company is intensifying R&D in high-end medical imaging equipment, focusing on CT, MR, and DSA products, which results in a temporary drag on profits due to increased R&D expenditures [5]. 3. Rising costs associated with expanding into overseas and high-tier hospital markets. The company is advancing its overseas market layout and enhancing its marketing and organizational investments in domestic high-tier hospitals, leading to increased costs [6]. Industry Perspective - The expected loss for WanDong Medical in 2025 is seen as a typical case of "transitional pressure" in the imaging equipment industry amid centralized procurement and structural upgrades. - High-end imaging equipment is gradually being included in more price-constrained procurement systems, making it difficult for domestic manufacturers to avoid temporary declines in gross margins, even with increased bid volumes. - The shift towards high-end, systematic, and overseas operations inherently requires longer cycles, higher R&D intensity, and heavier organizational investments. - The company has not retreated from its strategic goals but has chosen a path of "exchanging scale for time and investment for technological reserves" in the centralized procurement environment. This strategy may be unfavorable for profits in the short term but is worth observing from a medium to long-term perspective, especially in core areas like CT, MR, and DSA where domestic replacement is deepening [7]. Key Variables for the Future - The future performance will depend on the commercialization pace of high-end imaging products, the efficiency of overseas market order conversions, and the ability to rebalance product structure and gross margins post-centralized procurement [8].

Summary of WanDong Medical Conference Call Company Overview - **Company**: WanDong Medical - **Parent Company**: Midea Group - **Industry**: High-end medical equipment, focusing on CT, MR, and DSA technologies Key Points and Arguments Strategic Shift and Market Positioning - Since joining Midea Group in 2021, WanDong Medical has shifted its strategic focus towards the high-end medical equipment market, particularly in CT, MR, and DSA sectors, aiming to transition from traditional low to mid-end markets to high-end clients [2][5] - The company is actively expanding its overseas market presence, aligning with the "Belt and Road" initiative, which supports its internationalization strategy [2][5] Response to Market Challenges - The centralized procurement policy has provided WanDong Medical with opportunities to enter mainstream public hospital markets, despite facing pressure on gross margins [2][5] - The company is overcoming challenges by offering high cost-performance products and a flexible product matrix, launching new products like the 64-slice 128-layer cardiac CT and high-end 3T MRI [2][5] Internationalization and Collaboration - Midea Group's acquisition of Reiko International aims to enhance international business, with both companies complementing each other in product positioning and market reach [2][7] - Future capital operations may be implemented to avoid competition between WanDong and Reiko, ensuring optimal resource utilization [2][7] Innovation and R&D Focus - WanDong Medical is increasing its R&D investments, particularly in high-end medical imaging equipment, establishing a technology reserve system to enhance future product competitiveness [3][11] - The company is developing innovative products, including a helium-free MRI, which is expected to lead the market trend towards more sustainable technologies [12][18] Financial Performance and Market Strategy - Despite short-term profit pressures due to increased R&D and marketing expenses, the company is focused on long-term growth and value creation for shareholders [4][13] - WanDong Medical anticipates significant market share growth in mid to low-end CT and MRI markets, aiming for a top-three position in its segments by 2025 [15] AI and Smart Technology Integration - The company is investing in AI technologies for smart scanning, imaging, and management, aiming to transform imaging devices into intelligent systems [16][17] - Current projects include the development of smart DR systems and integrated diagnostic solutions for specific conditions like adolescent scoliosis [16][17] Future Outlook - WanDong Medical expects to maintain a strong growth trajectory, with a focus on high-end and innovative products, while expanding its international market share to 40-45% of total revenue by 2026 [15][19] - The company is committed to enhancing its operational efficiency and cost structure to improve overall profitability [11][14] Additional Important Insights - The company is strategically positioning itself to adapt to the ongoing changes in the medical equipment market, particularly with the implementation of centralized procurement policies [9][11] - WanDong Medical's approach to product differentiation and innovation is crucial for maintaining competitiveness against established players in the industry [12][19]

与此同时，公司持续加大研发投入，同时积极拓展海外市场并强化国内高等级医院的营销力度，助力公 司向大放、向高端、向海外的战略转型，但也导致净利润承压。 面对行业结构性升级挑战，公司引进专业研发技术人员，深化高端医学影像设备的全面布局，尤其是大 放品类的CT、MR和DSA。公司聚焦核心零部件及高性能设备研发，构建"研究一代、储备一代、开发 一代"的技术储备格局。同时，公司加速海外市场的覆盖和深耕，持续完善海外营销组织架构和职能体 系，通过实施海外驻点扩容、构建地域性服务中心等举措，有助提升医疗可及性。 近日，万东医疗（600055）发布公告称，预计2025年度实现归母净利润约亏损1.99亿元至2.57亿元，预 计扣除非经常性损益后的归母净利润约亏损2.13亿元至2.71亿元。 2025年度，公司为适应市场变化，适时优化了营销策略，通过更具竞争力的价格方案成功中标影像设备 项目，价格调整对毛利率产生了一定影响，导致净利润空间有所压缩。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 经财务部门初步测算，预计2025年度实现归属于母公司所有者的净利润为-19,873万元到-25,683万元， 与上年同期相比，将出现亏损。 预计2025年度实现归属于母公司所有者的扣除非经常性损益后的净利润为-21,323万元到-27,133万元， 与上年同期相比，将出现亏损。 （三）本期业绩预告数据未经会计师事务所审计。 二、上年同期经营业绩和财务状况 （一）公司2024年度利润总额为16,686万元，归属于母公司所有者的净利润为15,735万元，归属于母公 司所有者的扣除非经常性损益的净利润为14,242万元。 ● 业绩预告的具体适用情形：净利润为负值。 ● 北京万东医疗科技股份有限公司（以下简称"公司"）预计2025年度实现归属于母公司所有者的净利润 为-19,873万元到-25,683万元。预计2025年度实现归属于母公司所有者的扣除非经常性损益 ...

2025年度，公司持续加大研发投入，同时积极拓展海外市场并强化国内高等级医院的营销力度，助力公 司向大放、向高端、向海外的战略转型，但也导致净利润承压。面对行业结构性升级挑战，公司引进专 业研发技术人员，深化高端医学影像设备的全面布局，尤其是大放品类的CT、MR和DSA。公司聚焦核 心零部件及高性能设备研发，构建"研究一代、储备一代、开发一代"的技术储备格局。同时，公司加速 海外市场的覆盖和深耕，持续完善海外营销组织架构和职能体系，通过实施海外驻点扩容、构建地域性 服务中心等举措，有助提升"一带一路"国家和地区的医疗可及性。 证券之星消息，万东医疗发布业绩预告，预计2025年全年归属净利润亏损1.99亿元至2.57亿元。 公告中解释本次业绩变动的原因为： 2025年度，公司深度参与医疗设备集中采购，为适应市场变化，适时优化了营销策略，通过更具竞争力 的价格方案成功中标影像设备项目，价格调整对毛利率产生了一定影响，导致净利润空间有所压缩。 万东医疗2025年三季报显示，前三季度公司主营收入11.89亿元，同比上升8.73%；归母净利润-2720.98 万元，同比下降123.51%；扣非净利润-4457.54万元 ...

在距离圭亚那首都乔治敦约25公里的恩莫尔地区，6所地区医院之一的恩莫尔地区医院已成为当地地 标。恩莫尔地区医院建筑面积超6000平方米，崭新的医院大楼格外醒目。医院内部整洁明亮，挂号区、 住院区、急诊区、食堂等功能区域一应俱全。据介绍，医院设有75张住院床位、24小时运营的急诊科以 及其他多个专业科室，配备CT、数字化X射线设备、移动急救设备等来自中国的先进医疗设施，构建起 覆盖基础检查、精准诊断、专科治疗到急诊手术的全链条诊疗服务体系。 《人民日报》（2026年01月28日03版） "现在，当地居民在家门口就能获得专业护理。"恩莫尔地区医院首席执行官特蕾西·博维尔在接受人民 日报记者采访时表示，在该医院投运前，当地医疗只能依靠一家综合诊所。一旦当地居民有需要急诊、 外科手术的情况，就得辗转一个小时到乔治敦接受治疗。"现在，我们设有外科、妇产科等专业科室， 大多数情况都不用转诊，居民就能就近享受便利专业的医疗服务。"博维尔说。 责编：秦雅楠、卢思宇 "越来越多的居民都受益于这家医院。"家住医院附近的桑德拉·苏胡是土生土长的恩莫尔人。她说，看 着医院一天天建成，大家都感到欣喜。 在南美洲北部的圭亚那，濒临大西洋 ...

21世纪经济报道记者韩利明 为整治政府采购领域"内卷式"竞争，财政部日前印发《关于推动解决政府采购异常低价问题的通知》（下称"《通知》"），明 确将耗材使用量大的实验、医疗等仪器设备采购项目纳入重点管理范畴，从采购需求、审查范围、履约流程等维度划定监管红 线。 事实上，早在2024年12月，财政部便已印发试点通知，在北京、天津、上海、福建、广东自由贸易试验区和海南自由贸易港开 展异常低价问题试点工作；江西省也在2025年12月出台专项工作通知，推动政府采购从"低价导向"向"优质优价"转变。 在业内看来，医疗设备市场因政府采购占比高，近两年伴随行业竞争加剧，细分领域价格内卷现象愈发突出。此次《通知》的 落地实施，将进一步完善政府采购监管机制，引导行业从"价格战"转向理性竞价、良性竞争的轨道。 北京中医药大学卫生健康法学教授、博士生导师邓勇向21世纪经济报道记者指出，新规通过价格红线、全流程审查和履约监 管，从根源上遏制医疗设备领域的异常低价竞争。 "企业需从价格战转向技术+服务+合规的综合竞争，医院需建立全生命周期成本理念，监管部门需压实各方责任，共同推动行业 向优质优价转型。"邓勇教授表示，"行业洗牌不可避免 ...